Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
The molecular features that define clear cell renal cell carcinoma (ccRCC) initiation and
progression are being increasingly defined. The TRACERx Renal studies and others that …
progression are being increasingly defined. The TRACERx Renal studies and others that …
CK2 in cancer: cellular and biochemical mechanisms and potential therapeutic target
MMJ Chua, CE Ortega, A Sheikh, M Lee… - Pharmaceuticals, 2017 - mdpi.com
CK2 genes are overexpressed in many human cancers, and most often overexpression is
associated with worse prognosis. Site-specific expression in mice leads to cancer …
associated with worse prognosis. Site-specific expression in mice leads to cancer …
Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth
T Oshima, Y Niwa, K Kuwata, A Srivastava, T Hyoda… - Science …, 2019 - science.org
Compounds targeting the circadian clock have been identified as potential treatments for
clock-related diseases, including cancer. Our cell-based phenotypic screen revealed …
clock-related diseases, including cancer. Our cell-based phenotypic screen revealed …
Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration
Oncogenic Ras mutants, frequently detected in human cancers, are high-priority anticancer
drug targets. However, direct inhibition of oncogenic Ras mutants with small molecules has …
drug targets. However, direct inhibition of oncogenic Ras mutants with small molecules has …
PIN1 and CDK1 cooperatively govern pVHL stability and suppressive functions
J Chen, M Li, Y Liu, T Guan, X Yang, Y Wen… - Cell Death & …, 2023 - nature.com
The VHL protein (pVHL) functions as a tumor suppressor by regulating the degradation or
activation of protein substrates such as HIF1α and Akt. In human cancers harboring wild …
activation of protein substrates such as HIF1α and Akt. In human cancers harboring wild …
Genotype-phenotype relations of the von Hippel-Lindau tumor suppressor inferred from a large-scale analysis of disease mutations and interactors
Familiar cancers represent a privileged point of view for studying the complex cellular events
inducing tumor transformation. Von Hippel-Lindau syndrome, a familiar predisposition to …
inducing tumor transformation. Von Hippel-Lindau syndrome, a familiar predisposition to …
The pVHL neglected functions, a tale of hypoxia-dependent and-independent regulations in cancer
The von Hippel–Lindau protein (pVHL) is a tumour suppressor mainly known for its role as
master regulator of hypoxia-inducible factor (HIF) activity. Functional inactivation of pVHL is …
master regulator of hypoxia-inducible factor (HIF) activity. Functional inactivation of pVHL is …
Ancient evolutionary origin of intrinsically disordered cancer risk regions
Cancer is a heterogeneous genetic disease that alters the proper functioning of proteins
involved in key regulatory processes such as cell cycle, DNA repair, survival, or apoptosis …
involved in key regulatory processes such as cell cycle, DNA repair, survival, or apoptosis …
Systemic Therapy Options in VHL Disease
E Jonasch - Von Hippel-Lindau Disease: A Comprehensive Guide …, 2024 - Springer
Systemic therapy for von Hippel-Lindau (VHL) disease has been evolving over the past
decade in conjunction with our understanding of the molecular biology of VHL deficiency …
decade in conjunction with our understanding of the molecular biology of VHL deficiency …
The long form of pVHL is artifactually modified by serine protease inhibitor AEBSF
D Tarade, S He, J St‐Germain, A Petroff… - Protein …, 2020 - Wiley Online Library
Abstract von Hippel–Lindau protein (pVHL) is the tumor suppressor responsible for
ubiquitylating the hypoxia‐inducible factor (HIF) family of transcription factors for …
ubiquitylating the hypoxia‐inducible factor (HIF) family of transcription factors for …